Ovid commences Phase I trial of OV101 to treat Angelman / Fragile X syndromes

Biopharmaceutical firm Ovid Therapeutics has commenced the Phase I clinical trial of OV101 for the treatment of adolescents with Angelman syndrome or Fragile X syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news